- Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416. Dowlati, A., Robertson, K., Radivoyevitch, T., Waas, J., Ziats, N.P., Hartman, P., Abdul-Karim, F.W., Wasman, J.K., Jesberger, J., Lewin, J., McCrae, K., Ivy, P., Remick, S.C. Clin. Cancer Res. (2005)